Novartis PREVENT data shows Cosentyx helps patients realize early and lasting relief in axial spondyloarthritis.
Novartis, announced the full 52-week results from the Phase III PREVENT trial, which reinforce the substantial and sustained benefits of Cosentyx (secukinumab) across the axial spondyloarthritis (axSpA) spectrum… read more.

